B-type natriuretic peptide for diagnosis and treatment of congestive heart failure

Swiss Medical Weekly

Volumn 132, Issue 43-44, 2002, Pages 623-628

  Kuster, Gabriela M ^a   Tanner, Hildegard ^a   Printzen, Gert ^a   Suter, Thomas M ^a   Mohacsi, Paul ^a   Hess, Otto M ^a  

^a BERN UNIVERSITY HOSPITAL   (Switzerland)

Author keywords

Congestive heart failure; Natriuretic peptides; Neurohumoral stimulation

Indexed keywords

AMIODARONE; ANGIOTENSIN RECEPTOR ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BRAIN NATRIURETIC PEPTIDE; DIGITALIS; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; NITRIC ACID DERIVATIVE; SALICYLIC ACID; SPIRONOLACTONE; WARFARIN;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CONGESTIVE HEART FAILURE; DIAGNOSTIC VALUE; DISEASE MARKER; DISEASE SEVERITY; EXERCISE; FEMALE; HEART CATHETERIZATION; HEART LEFT VENTRICLE EJECTION FRACTION; HEART LEFT VENTRICLE ENDDIASTOLIC PRESSURE; HEART LEFT VENTRICLE FILLING PRESSURE; HEART LEFT VENTRICLE MASS; HOSPITALIZATION; HUMAN; MALE; PROGNOSIS; TWO DIMENSIONAL ECHOCARDIOGRAPHY; VASCULAR RESISTANCE; WALKING; WEIGHT REDUCTION;

EID: 0037079538     PISSN: 14247860     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (21)

1. Dao Q, Krishnaswamy P, Kazanegra R, Harrison A, Amirnovin R, Lenert L, Clopton P, Alberto J, Hlavin A, Maisel AS. Utility of B-tpye natriuretic peptide in the diagnosis of congestive heart failure in an urgent-care setting. J Am Coll Cardiol 2001;37:379-85.
2. Wallen T, Landahl S, Hedner T, Nako K, Saito Y. Brain natriuretic peptide predicts mortality in the elderly. Heart 1997;77:264-7.
3. Cheng V, Kazanegra R, Garcia A, Lenert L, Krishnaswamy P, Gardetto N, Clopton P, Maisel AS. A rapid bedside test for B-type natriuretic peptide predicts treatment outcomes in patients admitted for decompensated heart failure: A pilot study. J Am Coll Cardiol 2001;37:386-91.
4. Davidson NC, Naas AA, Hanson JK, Kennedy NS, Coutie WJ, Struthers AD. Comparison of atrial natriuretic peptide, B-type natriuretic peptide, and N-terminal proatrial natriuretic peptide as indicators of left ventricular systolic dysfunction. Am J Cardiol 1996;77:828-31.
5. Nagagawa O, Ogawa Y, Itoh H, Suga S, Komatsu Y, Kishimoto I. Rapid transcriptional activation and early mRNA turnover of BNP in cardiocyte hypertrophy: evidence for BNP as an "emergency" cardiac hormone against ventricular overload. J Clin Invest 1995;96:1280-7.
6. Sudoh T, Maekawa K, Kojima M, Minamino N, Kangawa K, Matsuo H. Cloning and sequence analysis of cDNA encoding as a precursor for human brain natriuretic peptide. Biochem Biophy Res Commun 1989;159:1427-34.
7. Yoshimura M, Yasue H, Okamura K et al. Different secretion pattern of atrial natriuretic peptide and brain natriuretic peptide in patients with congestive heart failure. Circulation 1993;87:464-9.
8. Nakao K, Ogawa Y, Suga S, Imura H. Molecular biology and biochemistry of the natriuretic peptide system. J Hypertens 19092;10:907-12.
9. Maeda K, Takayoshi T, Wada A, Hisanaga T, Kinoshita M. Plasma brain natriuretic peptide as a biochemical marker of high left ventricular end-diastolic pressure in patients with symptomatic left ventricular dysfunction. Am Heart J 1998;135:825-32.
10. The Task Force on Heart Failure of the European Society of Cardiology. Guidelines for the diagnosis of heart failure. Eur Heart J 1995;16:741-51.
11. Wright SP, Gamble G, Pomfret J, Muncaster S, Fisher S, Richards AM, Sharpe DN, Doughty RN. The accuracy of bedside brain natriuretic peptide measurement using a point-of-care meter. Eur J Heart Fail 2001;3 (Suppl 1):S11 (abstract).
12. Maisel AS. B-Type natriuretic peptide levels: a potential novel "white count" for congestive heart failure. J Card Fail 2001;7:183-93.
13. Nakao K, Mukoyama M, Hosoda K, Suga S, Ogawa Y, Saito Y, Shirakami G, Arai H, Jougasaki M, Imura H. Biosynthesis, secretion and receptor selectivity of human brain natriuretic peptide. Can J Physiol Pharamacol 1991;87:1402-12.
14. Troughton RW, Frampton CM, Yandle TG, Espiner EA, Nicholls MG, Richards AM. Treatment of heart failure guided by plasma amino terminal brain natriuretic peptide (N-BNP) concentrations. Lancet 2000;355:1126-30.
15. Kazanegra R, Cheng V, Gaccia A, Krishnaswamy P, Gasdetto N, Clopton P, Maisel AS. A rapid test for B-type natriuretic peptide (BNP) correlates with falling wedge pressure in patients treated for decompensated heart failure: a pilot study. J Card Fail 2001;7:21-9.
16. Tsutamoto T, Wada A, Maeda K, et al. Attenuation of compensation of endogenous cardiac natriuretic peptide system in chronic heart failure: prognostic role of plasma brain natriuretic peptide concentration in patients with chronic symptomatic left ventricular dysfunction. Circulation 1997;96:509-16.
17. Franciosa JA, Park M, Levine TB. Lack of correlation between exercise capacity and indexes of left ventricular performance in heart failure. Am J Cardiol 1981;47:33-9.
18. Lele SS, Macfarlane D, Morrison S, Thomson H, Khafagi F, Frenneaux M. Determinants of exercise capacity in patients with coronary artery disease and mild to moderate systolic dysfunction. Eur Heart J 1996;17:204-12.
19. Zugck C, Krüger C, Dürr S, Gerber SH, Haunstetter A, Homig K, Kübler W, Haass M. Is the six minute walk test a reliable substitute of peak oxygen uptake in patients with dilated cardiomyopathy? Eur Heart J 2000;21:540-9.
20. Cahalin LP, Mathier MA, Semigran MJ, Dec GW, diSalvo TG. The six-minute walk test predicts peak oxygen up-take and survival in patients with advanced heart failure. Chest 1996;110:325-32.
21. Roul G, Germain P, Barciss P. Does the 6-minute walk test predict the prognosis in patients with NYHA class II or III chronic heart failure? Am Heart J 1998;136:449-57.